Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma

The overall survival rate of patients with osteosarcoma has remained stagnant at 15–30% for several decades. Although immunotherapy has revolutionized the oncology field, largely attributed to the success of immune-checkpoint blockade, the durability and efficacy of anti-PD1 (programmed cell death p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingzhe, Li, Ye, Yang, Shoujun, Zhang, Lening, Wang, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593232/
https://www.ncbi.nlm.nih.gov/pubmed/31293882
http://dx.doi.org/10.1016/j.jbo.2019.100245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593232/
https://www.ncbi.nlm.nih.gov/pubmed/31293882
http://dx.doi.org/10.1016/j.jbo.2019.100245

Ejemplares similares